Acute Kidney Injury News and Research

RSS

Acute kidney injury (AKI) involves sudden damage to the kidneys or decrease in renal function that occurs over a few hours or days. The severity of the condition can vary from a minor loss of kidney function to kidney failure.

Potential breakthrough in treating acute kidney injury with ceramide-targeting drugs

Serious damage to short-term kidney function-known as acute kidney injury, or AKI-can be fatal and also increase the risk of irreversible chronic kidney disease. It can be triggered by stressors ranging from sepsis to heart surgery, and it affects more than half of ICU patients.

12 Nov 2025

Using estimated risks and preferences to justify intensive BP control in CKD patients

An analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) indicates that nearly all adults with chronic kidney disease (CKD) would have benefits that outweigh the harm from a systolic blood pressure target of <120 mm Hg compared with a target of <140 mm Hg. The findings will be presented at ASN Kidney Week 2025 November 5– 9.

8 Nov 2025

Weaning hospitalized patients from dialysis may restore kidney function

Weaning patients with acute kidney injury (AKI) from dialysis while they are still hospitalized may save them from remaining on the treatment for the rest of their lives, according to a new study led by UC San Francisco.

7 Nov 2025

Yale researchers develop new test for early leptospirosis detection

In a new study, Yale School of Medicine (YSM) researchers unveiled a novel diagnostic method for detecting leptospiral virulence-modifying (VM) proteins in the blood and urine of hamsters, an advance that could pave the way for early diagnosis of the tropical disease leptospirosis in humans and improved treatment options.

29 Sep 2025

Targeting mitochondrial biogenesis to improve outcomes in acute kidney injury

Acute kidney injury (AKI) remains a significant global health challenge, with high mortality rates and the potential for progression to chronic kidney disease.

18 Aug 2025

New therapies for acute kidney injury show promise

Acute kidney injury (AKI) is a severe renal disorder affecting approximately 10%-15% of hospitalized patients and up to 50% in intensive care units (ICUs). Its pathogenesis involves complex inflammatory regulatory mechanisms. As core components of the cytokine network, interleukins (ILs) exert pleiotropic effects in AKI development, extensively participating in inflammation, fibrosis, tissue injury repair, and remote organ damage.

18 Aug 2025

Study finds no evidence to suggest mild COVID-19 may cause long-term kidney damage

A new study of over 13 million people in England has found no evidence to suggest mild COVID-19 infection may cause long-term kidney damage.

19 Jun 2025

Vaccination linked to better kidney outcomes in hospitalized COVID-19 patients

Vaccinated patients hospitalized with COVID-19 who developed acute kidney injury had better outcomes than unvaccinated patients with the same condition, new research suggests.

14 Jun 2025

Pentoxifylline offers no survival benefit for severe alcohol-associated hepatitis

Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver decompensation, sAH is often accompanied by acute kidney injury (AKI), a complication that substantially worsens prognosis.

13 May 2025

Study: One in four early cardiogenic shock patients experience worse outcomes

In one of the largest studies of early cardiogenic shock (CS) patients, where blood flow is still functioning to vital organs, researchers demonstrated that 26% experienced worse outcomes, including care escalation, CS deterioration, or in-hospital mortality.

2 May 2025

Long COVID poses lasting health risks for young people

Long COVID can result in increased risk for a variety of serious health problems for young people, including those affecting the kidney, gut, and cardiovascular system, according to a group of new studies led by investigators at the Perelman School of Medicine at the University of Pennsylvania.

21 Apr 2025

Fluid restriction does not improve health in heart failure patients

People with heart failure have long been advised to limit the amount of fluids they consume each day to help reduce congestion, or the buildup of fluid in the lungs and extremities, but that advice provides no benefit, according to a study presented at the American College of Cardiology's Annual Scientific Session.

31 Mar 2025

Study finds 4F-PCC superior to frozen plasma in reducing bleeding after cardiac surgery

In patients experiencing excessive bleeding during cardiac surgery, a concentrated blood product containing proteins that help the blood clot was significantly more effective and caused fewer adverse effects than frozen plasma, the standard therapy, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.25).

29 Mar 2025

Harnessing lncRNAs for early diagnosis and intervention in acute kidney injury

A new review published in Genes & Diseases on long non-coding RNAs (lncRNAs) highlights their critical role in the development, diagnosis, and potential treatment of acute kidney injury (AKI) and chronic kidney disease (CKD). The findings emphasize the importance of exosomal lncRNAs, which function as molecular regulators in kidney pathology and hold promise for future biomarker discovery and therapeutic advancements.

11 Mar 2025

SPRINT analysis supports lower blood pressure targets for older adults

Results from the Systolic Blood Pressure Intervention Trial (SPRINT) have supported lower blood pressure targets among community-dwelling older adults with hypertension to reduce the risk of cardiovascular disease and early death, but intensive blood pressure lowering can also increase risks of developing acute kidney injury and experiencing dangerously low blood pressure.

19 Feb 2025

Glucarpidase shows promise in treating kidney toxicity from methotrexate

An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study by investigators at Mass General Brigham.

6 Jan 2025

Intravenous infusion of exenatide fails to reduce risks of complications in heart surgery patients

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce the risk of death, stroke or organ failure.

18 Nov 2024

New analysis confirms canagliflozin's cardiovascular and kidney benefits in older adults

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients' age.

26 Oct 2024

Study: GLP-1RA not associated with acute kidney injury risk during anti-cancer treatments

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear.